Atrial Fibrillation & Stroke Risk (CHA2DS2-VASc)

📋 Key Information Summary

📋

Atrial fibrillation (AF) confers a 4–5× increased stroke risk, with an annual stroke rate of ~5% in untreated non-valvular AF.
The CHA₂DS₂-VASc score is the recommended Australian tool for stroke risk stratification in non-valvular AF.
Oral anticoagulation (OAC) is indicated for men with CHA₂DS₂-VASc ≥1 and women with ≥2, balancing stroke prevention against bleeding risk.
Direct oral anticoagulants (DOACs: apixaban, dabigatran, edoxaban, rivaroxaban) are first-line for most patients with non-valvular AF.
Warfarin remains the OAC of choice for patients with mechanical heart valves, moderate-severe mitral stenosis, or severe renal impairment (eGFR <15 mL/min).
The HAS-BLED score assesses major bleeding risk; a score ≥3 indicates 'high risk' but is not a contraindication to OAC—rather, it prompts modifiable risk factor management.
Rhythm control strategies (pharmacological or catheter ablation) may be pursued for symptom improvement but do not replace the need for anticoagulation based on stroke risk.
Cardioversion (electrical or pharmacological) requires at least 3 weeks of therapeutic anticoagulation prior, or transoesophageal echocardiography (TOE) to exclude left atrial thrombus.
Special considerations apply for Aboriginal and Torres Strait Islander peoples, who experience higher AF prevalence and stroke mortality with reduced access to specialist care.
Regular monitoring of renal function (at least annually) is essential for DOAC dose adjustment and ongoing safety.
Reversal agents are available for all DOACs (idarucizumab for dabigatran; andexanet alfa for factor Xa inhibitors) and vitamin K for warfarin.
Patient education on adherence, signs of stroke/TIA, and bleeding is critical, alongside a personalised management plan.

Introduction & Australian Epidemiology

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, characterised by disorganised atrial electrical activity leading to an irregularly irregular ventricular response. In Australia, AF prevalence increases with age, affecting approximately 2–4% of the adult population overall and >10% of those aged ≥80 years. The condition significantly elevates the risk of cardioembolic stroke, heart failure, and mortality.

Without anticoagulation, AF carries an annual stroke risk of approximately 5%, with strokes tending to be more severe and disabling than non-AF-related strokes. The landmark meta-analysis by Hart et al. demonstrated that adjusted-dose warfarin reduces stroke risk by 64%, while antiplatelet therapy alone reduces it by only 22%. The advent of direct oral anticoagulants (DOACs) has provided options with superior safety profiles, leading to their adoption as first-line therapy for non-valvular AF in Australian and international guidelines.

In Australia, AF management is guided by the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand (CSANZ) guidelines, which endorse the CHA₂DS₂-VASc score for risk stratification and recommend a patient-centred approach to anticoagulation, integrating bleeding risk assessment (HAS-BLED) and regular review.

Stroke Risk Stratification (CHA₂DS₂-VASc Score)

The CHA₂DS₂-VASc score is the validated tool recommended by Australian guidelines for estimating stroke risk in patients with non-valvular AF. It expands upon the older CHADS₂ score by incorporating additional common risk factors.

Letter	Risk Factor	Points
C	Congestive heart failure (or left ventricular systolic dysfunction)	1
H	Hypertension	1
A₂	Age ≥75 years	2
D	Diabetes mellitus	1
S₂	Stroke, TIA, or thromboembolism history	2
V	Vascular disease (e.g., prior MI, peripheral arterial disease, aortic plaque)	1
A	Age 65–74 years	1
Sc	Sex category (female sex)	1

Interpretation & Anticoagulation Recommendation (non-valvular AF):

⚠️

Critical Thresholds: Oral anticoagulation (OAC) is recommended for men with a score ≥1 and women with a score ≥2. A score of 0 in men or 1 in women (where the single point is for female sex) is considered 'low risk' and OAC is generally not indicated.

Score 0 (men) or 1 (women, solely for sex): No antithrombotic therapy.
Score 1 (men) or 2 (women, with ≥1 non-sex point): OAC recommended.
Score ≥2 (men) or ≥3 (women): OAC strongly recommended.

Note: The score does not apply to patients with valvular AF (mechanical valve or at least moderate mitral stenosis), who require warfarin. It also does not capture all factors (e.g., chronic kidney disease, biomarkers like elevated NT-proBNP), which may inform individualised decisions.

Bleeding Risk Assessment (HAS-BLED)

The HAS-BLED score is a practical tool to quantify major bleeding risk in AF patients on anticoagulation. Its primary role is to identify modifiable bleeding risk factors, not to withhold anticoagulation in patients who otherwise have an indication.

Letter	Clinical Characteristic	Points
H	Hypension (uncontrolled, >160 mmHg systolic)	1
A	Abnormal renal function (dialysis, transplant, Cr ≥200 µmol/L) and/or liver function (cirrhosis, bilirubin >2× ULN, AST/ALT >3× ULN)	1 or 2
S	Stroke history	1
B	Bleeding history or predisposition (e.g., prior major bleed, anaemia)	1
L	Labile INR (TTR <60% if on warfarin)	1
E	Elderly (age >65 years)	1
D	Drugs (antiplatelets, NSAIDs) and/or alcohol (≥8 drinks/week)	1 or 2

Interpretation:

Score 0–2: Low-moderate bleeding risk.
Score ≥3: High bleeding risk. This should prompt: 1) Correction of modifiable factors (e.g., strict blood pressure control, treat anaemia, avoid concomitant NSAIDs/antiplatelets if possible, improve warfarin TTR). 2) More frequent review and monitoring. 3) Consideration of a DOAC over warfarin where appropriate (DOACs have a lower risk of intracranial haemorrhage).

🚨

Key Safety Point: A high HAS-BLED score is not a contraindication to anticoagulation. The risk of ischaemic stroke in high CHA₂DS₂-VASc patients usually outweighs the bleeding risk. The focus must be on mitigating modifiable risks.

Anticoagulation Choices (Warfarin vs DOACs)

Choice of oral anticoagulant is individualised based on patient factors, comorbidities, and preference. DOACs are preferred for non-valvular AF due to their predictable pharmacokinetics, fewer food/drug interactions, and no routine coagulation monitoring requirement.

Direct Oral Anticoagulants (DOACs)

💊

Apixaban

Eliquis® · Factor Xa inhibitor

Adult dose5 mg PO BD. Reduce to 2.5 mg BD if ≥2 of: age ≥80, weight ≤60 kg, serum creatinine ≥133 µmol/L.

Renal adjustmentAvoid if eGFR <15 mL/min. Use with caution if eGFR 15–25 mL/min.

PBS status✔ PBS General Benefit

💊

Rivaroxaban

Xarelto® · Factor Xa inhibitor

Adult dose20 mg PO daily with food. Reduce to 15 mg daily if eGFR 15–49 mL/min.

Renal adjustmentAvoid if eGFR <15 mL/min.

PBS status✔ PBS General Benefit

💊

Dabigatran

Pradaxa® · Direct thrombin inhibitor

Adult dose150 mg PO BD. Reduce to 110 mg BD if age ≥80, concomitant verapamil, or increased bleeding risk.

Renal adjustmentAvoid if eGFR <30 mL/min.

PBS status✔ PBS General Benefit

💊

Edoxaban

Lixiana® · Factor Xa inhibitor

Adult dose60 mg PO daily. Reduce to 30 mg daily if eGFR 15–50 mL/min, weight ≤60 kg, or concomitant P-gp inhibitors.

Renal adjustmentAvoid if eGFR <15 mL/min.

PBS status✔ PBS General Benefit

Warfarin

💊

Warfarin

Coumadin®, Marevan® · Vitamin K antagonist

Adult doseIndividualised dosing to target INR 2.0–3.0. Commence 2–5 mg daily, adjust based on INR.

Key monitoringINR. Target Time in Therapeutic Range (TTR) >65–70% for efficacy and safety.

PBS status✔ PBS General Benefit

Indications for Warfarin over DOACs

Mechanical heart valve.
Moderate to severe mitral stenosis (typically rheumatic).
Severe chronic kidney disease (eGFR <15 mL/min or on dialysis).
Antiphospholipid syndrome with previous thrombosis.
Patient preference or established stable INR control.

Perioperative Management

A standardised bridging protocol is essential. For DOACs, omission is based on renal function and procedure bleeding risk (typically 24–48 hours for low-risk procedures, 48–96 hours for high-risk). Warfarin is ceased 5 days pre-procedure, with LMWH bridging considered only for very high thrombotic risk.

Cardioversion & Rhythm Control

Rhythm control aims to restore and maintain sinus rhythm, improving symptoms and quality of life. It does not obviate the need for anticoagulation based on CHA₂DS₂-VASc score, as stroke risk persists from the underlying atrial myopathy.

Cardioversion Strategies

1

Conventional Anticoagulation

At least 3 weeks of therapeutic OAC (warfarin with INR 2.0–3.0, or DOAC at standard dose) must be completed before elective cardioversion.

2

TOE-Guided Cardioversion

An alternative if early cardioversion is desired. A transoesophageal echocardiogram (TOE) is performed to exclude left atrial appendage thrombus. If absent, cardioversion can proceed with heparin/DOAC bridging.

3

Post-Cardioversion Anticoagulation

Continue OAC for at least 4 weeks post-successful cardioversion, regardless of rhythm outcome. Long-term OAC is then guided by CHA₂DS₂-VASc score, not by apparent sinus rhythm.

Pharmacological Rhythm Control

Antiarrhythmic drugs (AADs) are used for maintenance of sinus rhythm. Choice depends on underlying structural heart disease.

Agent	Considerations
Flecainide	'Pill-in-the-pocket' for paroxysmal AF in structurally normal hearts. Avoid in coronary artery disease or significant LV dysfunction.
Amiodarone	Highly effective but limited by long-term organ toxicity (thyroid, liver, lung, cornea). Requires baseline and periodic monitoring.
Sotalol	Non-cardioselective beta-blocker with Class III effect. Monitor QT interval and renal function.
Dronedarone	Less effective than amiodarone, but fewer non-cardiac side effects. Contraindicated in NYHA Class III–IV heart failure.

Catheter Ablation

Pulmonary vein isolation (PVI) by catheter ablation is a Class I recommendation for symptomatic paroxysmal or persistent AF refractory to AADs. It is increasingly used as first-line therapy in selected patients. The procedure carries risks (e.g., ~1% risk of significant complications like cardiac tamponade, stroke, pulmonary vein stenosis). Post-ablation, anticoagulation is typically continued for at least 2 months and then based on CHA₂DS₂-VASc score.

Special Populations

🤰 Pregnancy

Anticoagulation: Warfarin is teratogenic (1st trimester). Use LMWH (e.g., enoxaparin 1 mg/kg BD, adjusted for anti-Xa) throughout pregnancy, switching to warfarin post-partum if breastfeeding is not planned. DOACs are contraindicated.

👶 Paediatrics

AF is rare. Anticoagulation is managed by paediatric cardiology. DOACs are not approved for those <18 years for AF; warfarin or LMWH are used.

👴 Elderly (≥75 years)

Higher bleeding risk but greater absolute stroke risk benefit from OAC. DOACs are preferred over warfarin due to lower intracranial haemorrhage risk. Dose reduction for age/weight/renal function is critical (apixaban 2.5 mg BD, dabigatran 110 mg BD).

🫘 Chronic Kidney Disease

eGFR 30–50 mL/min: Use DOAC with dose reduction as per product information. eGFR 15–30 mL/min: Use with caution; apixaban may be preferred. eGFR <15 mL/min or dialysis: Warfarin is the recommended OAC.

🫁 Hepatic Impairment

Avoid DOACs in Child-Pugh B/C cirrhosis due to altered metabolism and coagulopathy. Warfarin can be used with careful INR monitoring.

🦠 Immunocompromised

No specific AF alterations. Be mindful of drug interactions (e.g., azole antifungals are strong CYP3A4/P-gp inhibitors that increase DOAC levels).

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander peoples experience a higher prevalence of AF, earlier onset, and significantly worse cardiovascular outcomes, including a 1.5–2× higher stroke mortality compared to non-Indigenous Australians. Management must be culturally safe and address systemic barriers.

Epidemiology

AF prevalence is up to twice as high in Indigenous Australians, often with comorbid rheumatic heart disease (a valvular cause requiring warfarin).

Access & Follow-up

Geographic isolation and limited specialist services can hinder INR monitoring for warfarin and regular renal function checks for DOACs. Consider longer-interval monitoring where appropriate or utilisation of Aboriginal Health Workers/Practitioners.

Comorbidities

Higher rates of diabetes, chronic kidney disease, and rheumatic heart disease necessitate careful choice and dosing of anticoagulant (warfarin often required for rheumatic valve disease).

Health Literacy & Communication

Use clear language, pictorial aids, and engage with family and community. Explain the purpose of lifelong therapy and signs of stroke/bleeding.

Medication Access

Ensure PBS prescriptions are accessible. Remote area patients may need authority scripts arranged for DOACs or warfarin through local clinics.

📚 References

1. Brieger D, Amerena J, Attia J, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung Circ. 2018;27(10):1209-1266.
2. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498.
3. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018;154(5):1121-1201.
4. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2019;140(2):e125-e151.
5. Australian Institute of Health and Welfare (AIHW). Atrial fibrillation. Cat. no. CVD 89. Canberra: AIHW; 2022.
6. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
7. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
8. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.
9. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104.
10. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100.
11. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10):e275-e444.
12. National Aboriginal Community Controlled Health Organisation (NACCHO). Cultural safety in practice. 2023.